Read More

Jaguar Health Announces Publication In Breast Cancer Research And Treatment Of Investigator-Initiated Phase 2 HALT-D Study Of Crofelemer For Prevention Of Chemotherapy-Induced Diarrhea In Breast Cancer Patients

Results of the study provide the first proof-of-concept data for potential use of crofelemer - a novel, oral, plant-based, non-opioid antidiarrheal prescription medication - in breast cancer patients SAN FRANCISCO, CA /

JAGX

Read More

Aileron Therapeutics Presents Results From Phase 1 Study In Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest On Bone Marrow Stem Cells And Hair Follicles At EORTC-NCI-AACR International Conference

p53-mediated cell cycle arrest results demonstrate potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as well as chemotherapy-induced alopecia (hair loss) Study showed

ALRN

Read More

Immutep Announced Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the Independent Data Monitoring Committee (IDMC) for the randomised, controlled Phase IIb TACTI-003 trial has reviewed initial safety data and recommended continuing the trial with no modificatio

IMMP